Covered recipient · General Payments record
ALEXANDRE PAPADOPOULOS
General Payments · PY2023–2024
$381.42
- Reported across 12 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $322.90 | 9 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $97.27 | 1 |
| Edwards Lifesciences Corporation | $81.19 | 1 |
| Merck Sharp & Dohme Corporation | $34.85 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25.66 | 1 |
| CATALYST PHARMACEUTICALS, INC. | $25.25 | 1 |
| Neurelis, Inc. | $21.31 | 1 |
| Amgen Inc. | $19.69 | 1 |
| Janssen Pharmaceuticals, Inc | $17.68 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
Program year 2024 2023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $97.27 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105177408 | CMS |
| Amgen Inc. | $19.69 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111669468 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25.66 | 12/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118137840 | CMS |
| CATALYST PHARMACEUTICALS, INC. | $25.25 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144453833 | CMS |
| Edwards Lifesciences Corporation | $81.19 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138803070 | CMS |
| Janssen Pharmaceuticals, Inc | $17.68 | 09/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078063486 | CMS |
| Merck Sharp & Dohme LLC | $20.39 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141906707 | CMS |
| Merck Sharp & Dohme LLC | $14.46 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141811837 | CMS |
| Neurelis, Inc. | $21.31 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145650116 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.